Welcome to our dedicated page for SHUTTLE PHARMACTCLS HLDGS SEC filings (Ticker: SHPH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking a clinical-stage biotech like Shuttle Pharmaceuticals means wading through pages of radiation-sensitizer chemistry, trial protocols, and financing footnotes. If finding R&D burn rates or decoding licensing terms inside a 10-K feels overwhelming, you’re not alone.
Stock Titan solves that problem. Our AI surfaces the numbers and narrative that matter—cash runway, Phase 2 milestones, dilution risks—directly from every filing type. Need the Shuttle Pharmaceuticals annual report 10-K simplified? We highlight how Ropidoxuridine’s glioblastoma study influences revenue projections. Curious about a fresh capital raise? The latest Shuttle Pharmaceuticals 8-K material events explained appear with plain-English context the moment EDGAR posts.
Here’s what you’ll find on this page:
- Real-time alerts for Shuttle Pharmaceuticals Form 4 insider transactions real-time, so you can see when executives buy or sell shares.
- Concise AI notes inside every Shuttle Pharmaceuticals quarterly earnings report 10-Q filing, turning trial-cost tables into readable trends.
- Side-by-side comparisons of equity issuances, royalty obligations, and Shuttle Pharmaceuticals proxy statement executive compensation disclosures.
Whether you’re monitoring Shuttle Pharmaceuticals insider trading Form 4 transactions before a data read-out or seeking a quick Shuttle Pharmaceuticals earnings report filing analysis, our platform answers the exact questions professionals ask: “understanding Shuttle Pharmaceuticals SEC documents with AI”. All filings, all the time—explained simply.
Shuttle Pharmaceuticals Holdings, Inc. (SHPH) filed an initial Form 3 reporting that Adam V. Chambers is a director as of 09/08/2025. The filing lists Mr. Chambers' business address in Gaithersburg, MD and indicates he directly beneficially owns 0 shares of the issuer's common stock and holds no derivative securities. The form is an initial disclosure of a director's ownership and contains no reported holdings or exercisable awards.
Armistice Capital, LLC and Steven Boyd filed an amended Schedule 13G reporting shared beneficial ownership of 56,237 shares of Shuttle Pharmaceuticals Holdings, Inc. common stock, representing 4.99% of the class. Armistice Capital is the investment manager of Armistice Capital Master Fund Ltd., the direct holder of the shares, and pursuant to an investment management agreement exercises voting and investment power over those securities. Mr. Boyd, as managing member of Armistice Capital, is reported with the same shared voting and dispositive power. The filing states the position is held in the ordinary course of business and not for the purpose of changing or influencing control.
Steven M. Richards, a director of Shuttle Pharmaceuticals Holdings (SHPH), was granted 29,240 Restricted Stock Units (RSUs) on 08/08/2025, as reported on a Form 4 signed 08/12/2025. The filing states each RSU represents the contingent right to receive one share of common stock at no cash price.
One-third of the RSUs will vest on each of 08/08/2026, 08/08/2027 and 08/08/2028, meaning the award converts into a total of 29,240 shares if all vest according to the stated schedule. The Form 4 lists the ownership form as direct and shows the grant was reported under a non-cash equity award.
Shuttle Pharmaceuticals director Oleh Nabyt was granted 29,240 restricted stock units (RSUs) on 08/08/2025. Each RSU represents the contingent right to receive one share of common stock and is reported with a $0 price. The RSUs vest in three equal installments: one-third on 08/08/2026, one-third on 08/08/2027 and one-third on 08/08/2028. The award is reported as a direct beneficial holding and, if fully vested and converted, would result in receipt of up to 29,240 shares of common stock.
George Scorsis, a director of Shuttle Pharmaceuticals Holdings (SHPH), was granted 29,240 Restricted Stock Units (RSUs) on 08/08/2025. Each RSU represents the contingent right to receive one share of common stock. The award is reported as direct beneficial ownership by the reporting person.
One-third of the RSUs vest on each of 08/08/2026, 08/08/2027 and 08/08/2028, meaning up to 29,240 common shares may be issued to satisfy the award over three years if vesting conditions are met. The grant is a standard equity compensation award for a board member with a multi-year retention schedule.
Joseph Tung, a director of Shuttle Pharmaceuticals Holdings (SHPH), was granted 29,240 restricted stock units (RSUs) on 08/08/2025. Each RSU represents the contingent right to receive one share of common stock and the award was recorded at $0. The RSUs vest in three equal installments, with one-third vesting on each of 08/08/2026, 08/08/2027 and 08/08/2028, and the reported ownership form is direct. Following this reported transaction, the RSUs correspond to 29,240 underlying shares.
The filing discloses an equity award that aligns a director with shareholder interests via long-term vesting, but it does not provide the company’s total outstanding share count or other compensation terms needed to assess dilution or material financial impact.
Timothy J. Lorber, Chief Financial Officer of Shuttle Pharmaceuticals Holdings, Inc. (SHPH), was granted a total of 54,094 restricted stock units (RSUs) in transactions dated 08/08/2025. Each RSU represents a contingent right to receive one share of common stock and the grants were reported on a Section 16 Form 4.
The awards are split into two grants: 29,240 RSUs that vest one-third on each of 08/08/2026, 08/08/2027 and 08/08/2028, and 24,854 RSUs that vest on 02/08/2026. Both grants show an acquisition price of $0 and are held in a direct ownership form.
FAQ
What is the current stock price of SHUTTLE PHARMACTCLS HLDGS (SHPH)?
What is the market cap of SHUTTLE PHARMACTCLS HLDGS (SHPH)?
